Nag S, Shah V
Int J Radiat Oncol Biol Phys. 1986 Jun;12(6):1003-5. doi: 10.1016/0360-3016(86)90398-6.
Hemibody irradiation (HBI) of 8 Gy has been shown to produce pain relief in widespread metastatic disease. The major problems occurred with high dose (over 6 Gy) to the upper hemibody. Because 8 Gy lower HBI was well tolerated, we decided to study the efficacy and tolerance of even higher radiation doses given to the lower hemibody. Nineteen patients with widespread metastatic cancers in the lower hemibody were treated from 1982 to 1984 with 16 Gy (8 Gy one week apart) to the lower hemibody (from top of iliac crest to knee joint) after premedication with an antiemetic. All the patients tolerated this high dose, lower HBI well, except for two patients who had slight nausea and vomiting, and one patient who had moist reaction in the perineum. There was no significant bone marrow depression. All patients had improvement in performance status and had prompt pain relief, ten (53%) with complete pain relief and nine (47%) with partial pain relief. The median duration of pain relief was 5 months. Ten of the 15 patients who died were pain-free at the time of death. The four patients still living are free of pain. The median survival was 7 months, and five patients survived 1 year. High dose (8 Gy X 2 spaced one week apart), lower HBI produces prolonged, prompt and effective palliation of pain with minimal morbidity and is well tolerated. It probably does not prolong survival. Because it requires only two treatments spaced one week apart, it is a very convenient and cost effective regimen for the sick and elderly patient.
8Gy的半身照射(HBI)已被证明可缓解广泛转移性疾病引起的疼痛。主要问题出现在对上半身给予高剂量(超过6Gy)照射时。由于8Gy的下半身HBI耐受性良好,我们决定研究给予下半身更高辐射剂量的疗效和耐受性。1982年至1984年,对19名下半身广泛转移性癌症患者在使用止吐药进行预处理后,对下半身(从髂嵴顶部至膝关节)给予16Gy(分两周,每周8Gy)照射。除两名患者有轻微恶心和呕吐,一名患者会阴部出现湿性反应外,所有患者对这种高剂量的下半身HBI耐受性良好。未出现明显的骨髓抑制。所有患者的身体状况均有改善,疼痛迅速缓解,10例(53%)完全缓解,9例(47%)部分缓解。疼痛缓解的中位持续时间为5个月。15名死亡患者中有10名在死亡时无痛。仍在世 的4名患者也无痛。中位生存期为7个月,5名患者存活了1年。高剂量(8Gy×2,间隔一周)下半身HBI可产生持久、迅速且有效的疼痛缓解,发病率最低且耐受性良好。它可能不会延长生存期。由于仅需间隔一周进行两次治疗,对于患病和老年患者来说,这是一种非常方便且经济有效的治疗方案。